Africa: TB Alliance Announces European Commission Authorisation of New Treatment for Highly Drug-Resistant Tuberculosis

[TB Alliance] PRETORIA (3 August 2020)--Pretomanid, a novel compound developed by the non-profit organization TB Alliance, has been granted a conditional marketing authorisation by the European Commission (EC) for treating highly drug-resistant forms of pulmonary tuberculosis (TB).[i] The new drug was authorised as part of a three-drug, six month, all-oral regimen for the treatment of adults with extensively drug-resistant TB (XDR-TB) or multidrug-resistant TB (MDR-TB) who are treatment-intolerant or non-responsive
Source: AllAfrica News: Tuberculosis - Category: Infectious Diseases Source Type: news